301 related articles for article (PubMed ID: 18375895)
1. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
Spurdle AB; Lakhani SR; Healey S; Parry S; Da Silva LM; Brinkworth R; Hopper JL; Brown MA; Babikyan D; Chenevix-Trench G; Tavtigian SV; Goldgar DE;
J Clin Oncol; 2008 Apr; 26(10):1657-63. PubMed ID: 18375895
[TBL] [Abstract][Full Text] [Related]
2. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Chenevix-Trench G; Healey S; Lakhani S; Waring P; Cummings M; Brinkworth R; Deffenbaugh AM; Burbidge LA; Pruss D; Judkins T; Scholl T; Bekessy A; Marsh A; Lovelock P; Wong M; Tesoriero A; Renard H; Southey M; Hopper JL; Yannoukakos K; Brown M; Easton D; Tavtigian SV; Goldgar D; Spurdle AB;
Cancer Res; 2006 Feb; 66(4):2019-27. PubMed ID: 16489001
[TBL] [Abstract][Full Text] [Related]
3. RNA-based analysis of BRCA1 and BRCA2 gene alterations.
Bonatti F; Pepe C; Tancredi M; Lombardi G; Aretini P; Sensi E; Falaschi E; Cipollini G; Bevilacqua G; Caligo MA
Cancer Genet Cytogenet; 2006 Oct; 170(2):93-101. PubMed ID: 17011978
[TBL] [Abstract][Full Text] [Related]
4. Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation.
Gómez-García EB; Ambergen T; Blok MJ; van den Wijngaard A
J Clin Oncol; 2005 Apr; 23(10):2185-90. PubMed ID: 15800311
[TBL] [Abstract][Full Text] [Related]
5. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
[TBL] [Abstract][Full Text] [Related]
6. Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms.
Pettigrew C; Wayte N; Lovelock PK; Tavtigian SV; Chenevix-Trench G; Spurdle AB; Brown MA
Breast Cancer Res; 2005; 7(6):R929-39. PubMed ID: 16280041
[TBL] [Abstract][Full Text] [Related]
7. Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability.
Lovelock PK; Wong EM; Sprung CN; Marsh A; Hobson K; French JD; Southey M; Sculley T; Pandeya N; Brown MA; Chenevix-Trench G; Spurdle AB; McKay MJ;
Breast Cancer Res Treat; 2007 Sep; 104(3):257-66. PubMed ID: 17063265
[TBL] [Abstract][Full Text] [Related]
8. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
[TBL] [Abstract][Full Text] [Related]
9. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
Osorio A; Milne RL; Honrado E; Barroso A; Diez O; Salazar R; de la Hoya M; Vega A; Benítez J
Hum Mutat; 2007 May; 28(5):477-85. PubMed ID: 17279547
[TBL] [Abstract][Full Text] [Related]
10. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
Maillet P; Chappuis PO; Khoshbeen-Boudal M; Sciretta V; Sappino AP;
Cancer Genet Cytogenet; 2006 Aug; 169(1):62-8. PubMed ID: 16875939
[TBL] [Abstract][Full Text] [Related]
11. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
[TBL] [Abstract][Full Text] [Related]
12. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
van der Hout AH; van den Ouweland AM; van der Luijt RB; Gille HJ; Bodmer D; Brüggenwirth H; Mulder IM; van der Vlies P; Elfferich P; Huisman MT; ten Berge AM; Kromosoeto J; Jansen RP; van Zon PH; Vriesman T; Arts N; Lange MB; Oosterwijk JC; Meijers-Heijboer H; Ausems MG; Hoogerbrugge N; Verhoef S; Halley DJ; Vos YJ; Hogervorst F; Ligtenberg M; Hofstra RM
Hum Mutat; 2006 Jul; 27(7):654-66. PubMed ID: 16683254
[TBL] [Abstract][Full Text] [Related]
13. cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Zhang L; Bacares R; Boyar S; Hudis C; Nafa K; Offit K
Mutat Res; 2009 Apr; 663(1-2):84-9. PubMed ID: 19070627
[TBL] [Abstract][Full Text] [Related]
14. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
[TBL] [Abstract][Full Text] [Related]
15. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
Malacrida S; Agata S; Callegaro M; Casella C; Barana D; Scaini MC; Manoukian S; Oliani C; Radice P; Barile M; Menin C; D'Andrea E; Montagna M
J Clin Oncol; 2008 Jan; 26(1):26-31. PubMed ID: 18165637
[TBL] [Abstract][Full Text] [Related]
17. Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer.
Wappenschmidt B; Fimmers R; Rhiem K; Brosig M; Wardelmann E; Meindl A; Arnold N; Mallmann P; Schmutzler RK
Breast Cancer Res; 2005; 7(5):R775-9. PubMed ID: 16168123
[TBL] [Abstract][Full Text] [Related]
18. Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC.
Kim BY; Lee DG; Lee KR; Han SH; Surendran S; Han CW; Chung N
Biochem Biophys Res Commun; 2006 Oct; 349(2):604-10. PubMed ID: 16949048
[TBL] [Abstract][Full Text] [Related]
19. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
[TBL] [Abstract][Full Text] [Related]
20. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
